Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Yao-Chang Xu | Founder, Chairman of the Board & CEO | 4.62M | -- | 1957 |
| Dr. Hongping Yu | Co-Founder, Jt Co Secretary, Senior VP of Chemistry, Chief Scientific Officer & Executive Director | 3.19M | -- | 1968 |
| Dr. Zhui Chen | Co-Founder, Senior VP of Biology, Chief Scientific Officer & Executive Director | 3.3M | -- | 1974 |
| Dr. Zidong Zhang | Chief Financial Officer | -- | -- | 1981 |
| Ms. Jia Feng | VP of HR and Operations & Head of Human Resource | -- | -- | -- |
| Mr. Yongyi Li | General Counsel | -- | -- | 1976 |
| Dr. Zhen Zhang | VP of CMC & Head of Chemistry, Manufacturing and Controls | -- | -- | 1973 |
| Dr. Jing Ji | Chief Medical Officer | -- | -- | 1970 |
| Ms. Yin Wah Chan FCCA, FCIS, FCS, HKICS | Joint Company Secretary | -- | -- | 1975 |
Abbisko Cayman Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 275
Description
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of fexagratinib and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available